Visfatin (Nampt) and ghrelin as novel markers of carotid atherosclerosis in patients with type 2 diabetes

Experimental and Clinical Endocrinology and Diabetes

Volumn 118, Issue 2, 2010, Pages 75-80

  Kadoglou, N P E ^a,b   Sailer, N ^a   Moumtzouoglou, A ^a   Kapelouzou, A ^b   Tsanikidis, H ^a   Vitta, I ^a   Karkos, C ^c   Karayannacos, P E ^b   Gerasimidis, T ^c   Liapis, C D ^d  

^a Aristotle University of Thessaloniki   (Greece)

^b BIOMEDICAL RESEARCH FOUNDATION   (Greece)

^c ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^d UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Adiposity; Atherosclerosis; Carotid intima media thickness; Ghrelin; Type 2 diabetes; Visfatin (nampt)

Indexed keywords

ANTIHYPERTENSIVE AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; FIBRINOGEN; GHRELIN; GLUCOSE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; TRIACYLGLYCEROL;

ADULT; AGED; ANTHROPOMETRIC PARAMETERS; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROSIS; BLOOD PRESSURE; BLOOD SAMPLING; BODY MASS; CAROTID ARTERY; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETIC PATIENT; DISEASE ASSOCIATION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; INSULIN RESISTANCE; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL; ULTRASOUND; WAIST HIP RATIO;

AGED; ANALYSIS OF VARIANCE; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BLOOD PRESSURE; BODY MASS INDEX; C-REACTIVE PROTEIN; CAROTID ARTERIES; CAROTID ARTERY DISEASES; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; DOWN-REGULATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GHRELIN; HUMANS; INSULIN RESISTANCE; MALE; MIDDLE AGED; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; STATISTICS, NONPARAMETRIC; TUNICA INTIMA;

EID: 77649164023     PISSN: 09477349     EISSN: 14393646     Source Type: Journal    
DOI: 10.1055/s-0029-1237360     Document Type: Article

References (34)

1. Bastard JP, Maachi M, Lagathu C, etal. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw 2006 17 4-12 Superfluous sentence
2. Beauloye V, Zech F, Tran HT, etal. Determinants of early atherosclerosis in obese children and adolescents. J Clin Endocrinol Metab 2007 92 3025-3032
3. Berndt J, Klöting N, Kralisch S, etal. Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. Diabetes 2005 54 2911-2916
4. Blher M. Adipose tissue dysfunction in obesity. Exp Clin Endocrinol Diabetes 2009 117 241-250
5. Chen MP, Chung FM, Chang DM, etal. Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2006 91 295-299
6. Clodi M, Resl M, Stelzeneder D, etal. Interactions of glucose metabolism and chronic heart failure. Exp Clin Endocrinol Diabetes 2009 117 99-106
7. Dahl TB, Yndestad A, Skjelland M, etal. Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: possible role in inflammation and plaque destabilization. Circulation 2007 115 972-980
8. Despres JP. Abdominal obesity: the most prevalent cause of the metabolic syndrome and related cardiometaboli risk. Eur Heart J 2006 Suppl 6 B4-B12
9. Dixit VD, Schaffer EM, Pyle RS, etal. Ghrelin inhibits leptin- and activation-induced proinflammatory cytokine expression by human monocytes and T cells. J Clin Invest 2004 114 57-66
10. Dogru T, Sonmez A, Tasci I, etal. Plasma visfatin levels in patients with newly diagnosed and untreated type 2 diabetes mellitus and impaired glucose tolerance. Diabetes Res Clin Pract 2007 76 24-29
11. Fukuhara A, Matsuda M, Nishizawa M, etal. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005 307 426-430 (Pubitemid 40139988)
12. Garca EA, Korbonits M. Ghrelin and cardiovascular health. Curr Opin Pharmacol 2006 6 142-147
13. Gens BB, Granada ML, Alonso N, etal. Ghrelin, glucose homeostasis, and carotid intima media thickness in kidney transplantation. Transplantation 2007 84 1248-1254
14. Henry RR. Insulin resistance: From predisposing factor to therapeutic target in type 2 diabetes. Clin Ther 2003 25 (Suppl B) B47-B63
15. Kathiresan S, Larson MG, Keyes MJ, etal. Assessment by cardiovascular magnetic resonance, electron beam computed tomography, and carotid ultrasonography of the distribution of subclinical atherosclerosis across Framingham risk strata. Am J Cardiol 2007 99 310-314
16. Katugampola SD, Pallikaros Z, Davenport AP. [125I-His(9)]-ghrelin, a novel radioligand for localizing GHS orphan receptors in human and rat tissue: up-regulation of receptors with athersclerosis. Br J Pharmacol 2001 134 143-149
17. Kojima M, Hosoda H, Date Y, etal. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999 402 656-660
18. Korbonits M, Goldstone AP, Gueorguiev M, etal. Ghrelin a hormone with multiple functions. Front Neuroendocrinol 2004 25 27-68
19. Kotani K, Sakane N, Saiga K, etal. Serum ghrelin and carotid atherosclerosis in older Japanese people with metabolic syndrome. Arch Med Res 2006 37 903-906
20. Lopez-Bermejo A, Chico-Julia B, Fernandez-Balsells M, etal. Serum visfatin increases with progressive -cell deterioration. Diabetes 2006 55 2871-2875
21. Pöykkö SM, Kellokoski E, Ukkola O, etal. Plasma ghrelin concentrations are positively associated with carotid artery atherosclerosis in males. J Intern Med 2006 260 43-52
22. Pöykkö SM, Kellokoski E, Horkko S, etal. Low plasma ghrelin is associated with insulin resistance, hypertension, and the prevalence of type 2 diabetes. Diabetes 2003 52 2546-2553
23. Roman MJ, Naqvi TZ, Gardin JM, etal American Society of Echocardiography; Society for Vascular Medicine and Biology. American society of echocardiography report. Clinical application of non-invasive vascular ultrasound in cardiovascular risk stratification: a report from the American Society of Echocardiography and the Society for Vascular Medicine and Biology. Vasc Med 2006 11 201-211
24. Ross R. Atherosclerosis an inflammatory disease. N Engl J Med 1999 340 115-126
25. Russell M, Fleg JL, Galloway WJ, etal. Examination of lower targets for low-density lipoprotein cholesterol and blood pressure in diabetes the Stop Atherosclerosis in Native Diabetics Study (SANDS). Am Heart J 2006 152 867-875
26. Salonen R, Seppnen K, Rauramaa R, etal. Prevalence of carotid atherosclerosis and serum cholesterol levels in eastern Finland. Arteriosclerosis 1988 8 788-792
27. Sandeep S, Velmurugan K, Deepa R, etal. Serum visfatin in relation to visceral fat, obesity, and type 2 diabetes mellitus in Asian Indians. Metabolism 2007 56 565-570
28. Sepulveda JL, Mehta JL. C-reactive protein and cardiovascular disease: a critical appraisal. Curr Opin Cardiol 2005 20 407-416
29. Skilton MR, Celermajer DS. The effects of obesity-related peptides on the vasculature. Curr Vasc Pharmacol 2006 4 79-85
30. Ueno H, Shiiya T, Mizuta M, etal. Plasma ghrelin concentrations in different clinical stages of diabetic complications and glycemic control in Japanese diabetics. Endocr J 2007 54 895-902
31. Ukkola O, Poykko S, Paivansalo M, etal. Interactions between ghrelin, leptin and IGF-I affect metabolic syndrome and early atherosclerosis. Ann Med 2008 40 465-473
32. Varma V, Yao-Borengasser A, Rasouli N, etal. Human visfatin expression: relationship to insulin sensitivity, intramyocellular lipids, and inflammation. J Clin Endocrinol Metab 2007 92 666-672
33. Yano Y, Toshinai K, Inokuchi T, etal. Plasma des-acyl ghrelin, but not plasma HMW adiponectin, is a useful cardiometabolic marker for predicting atherosclerosis in elderly hypertensive patients. Atherosclerosis 2009 590-594
34. Zhong M, Tan HW, Gong HP, etal. Increased serum visfatin in patients with metabolic syndrome and carotid atherosclerosis. Clin Endocrinol (Oxf) 2008 69 878-884